The regulatory roles of RNA-binding proteins in the tumour immune microenvironment of gastrointestinal malignancies DOI Creative Commons
Dongqi Li, Xiangyu Chu, Weikang Liu

et al.

RNA Biology, Journal Year: 2024, Volume and Issue: 22(1), P. 1 - 14

Published: Dec. 24, 2024

The crosstalk between the tumour immune microenvironment (TIME) and cells promote evasion resistance to immunotherapy in gastrointestinal (GI) tumours. Post-transcriptional regulation of genes is pivotal GI tumours progression, RNA-binding proteins (RBPs) serve as key regulators via their domains. RBPs may exhibit either anti-tumour or pro-tumour functions by influencing TIME through modulation mRNAs non-coding RNAs expression, well post-transcriptional modifications, primarily N6-methyladenosine (m6A). Aberrant RBPs, such HuR YBX1, typically enhances escape impacts prognosis patients. Further, while targeting offers a promising strategy for improving cancers, mechanisms which regulate these remain poorly understood, therapeutic application still its early stages. This review summarizes current advances exploring roles regulating expression effect on tumours, then providing theoretical insights RBP-targeted cancer therapies.

Language: Английский

The regulatory roles of RNA-binding proteins in the tumour immune microenvironment of gastrointestinal malignancies DOI Creative Commons
Dongqi Li, Xiangyu Chu, Weikang Liu

et al.

RNA Biology, Journal Year: 2024, Volume and Issue: 22(1), P. 1 - 14

Published: Dec. 24, 2024

The crosstalk between the tumour immune microenvironment (TIME) and cells promote evasion resistance to immunotherapy in gastrointestinal (GI) tumours. Post-transcriptional regulation of genes is pivotal GI tumours progression, RNA-binding proteins (RBPs) serve as key regulators via their domains. RBPs may exhibit either anti-tumour or pro-tumour functions by influencing TIME through modulation mRNAs non-coding RNAs expression, well post-transcriptional modifications, primarily N6-methyladenosine (m6A). Aberrant RBPs, such HuR YBX1, typically enhances escape impacts prognosis patients. Further, while targeting offers a promising strategy for improving cancers, mechanisms which regulate these remain poorly understood, therapeutic application still its early stages. This review summarizes current advances exploring roles regulating expression effect on tumours, then providing theoretical insights RBP-targeted cancer therapies.

Language: Английский

Citations

1